FDA Accepts Axsome Therapeutics NDA for AXS-07

FDA Accepts Axsome Therapeutics NDA for AXS-07

Sep 14, 2021 | News, Regulatory

Biopharmaceutical company Axsome Therapeutics, known for developing innovative therapies for central nervous system (CNS) disorders, announced that the FDA (Food and Drug Administration) has accepted their New Drug Application (NDA) for AXS-07 for acute migraine...